Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Actinogen Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Actinogen Medical şirketinin toplam hissedar öz sermayesi A$19.7M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$21.3M ve A$1.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$9.45m
Eşitlik	AU$19.70m
Toplam yükümlülükler	AU$1.62m
Toplam varlıklar	AU$21.31m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Aug 09

Recent updates

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Apr 30

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Nov 16

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Aug 02

We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth

Apr 12

We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely

Nov 28

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Aug 09

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Apr 07

We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn

Oct 24

Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business

Jul 11

We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow

Mar 27

How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?

Jan 07

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ACW 'nin kısa vadeli varlıkları ( A$18.9M ) kısa vadeli yükümlülüklerini ( A$1.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: ACW şirketinin kısa vadeli varlıkları ( A$18.9M ) uzun vadeli yükümlülüklerini ( A$258.4K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ACW borçsuzdur.

Borcun Azaltılması: ACW son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ACW son raporlanan serbest nakit akışına göre 7 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: ACW serbest nakit akışı her yıl % 11.6 1 yıl yetecek nakit akışına sahip olacaktır.

Actinogen Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth

We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Recent updates

Actinogen Medical Limited, Annual General Meeting, Nov 14, 2024

New major risk - Revenue and earnings growth

Actinogen Medical Limited Announces Further Positive Results on Depression in the XanCIDD Phase 2A Trial

Actinogen Medical Limited as Announces Achievement of Clinically and Statically Significant Superiority of Xanamem over Placebo on Depression in Xanacidd Phase 2A Trial

New minor risk - Market cap size

Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker

New major risk - Revenue and earnings growth

Actinogen Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial

New major risk - Share price stability

Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Actinogen Medical Limited Announces CFO Changes

AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston

New minor risk - Share price stability

Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results

New minor risk - Shareholder dilution

Actinogen Medical Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

New major risk - Financial position

Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention

We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 11%

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Ltd Announces Receipt of Agreement from US Food and Drug Administration Agrees to Six-Month Phase 2b Alzheimers Disease Trial

Actinogen Medical Limited Announces First Patient Treated in Depression and Cognitive Impairment Phase 2 Clinical Trial

Actinogen Medical Limited Announces First Patient Treated in XanaCIDD Phase 2 Depression Trial

We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely

Price target increased to AU$0.15

Independent Non-Executive Director exercised options to buy AU$180k worth of stock.

MD, CEO & Director recently bought AU$94k worth of stock

Actinogen Medical Limited Announces Positive Alzheimers Disease Clinical Results

Actinogen Medical Limited, Annual General Meeting, Nov 16, 2022

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Actinogen Medical Limited Announces Phase 2 Trials in Alzheimer's Disease and Depression

Actinogen Medical Limited Announces Phase 2 Trial Designs for AD & MDD

MD, CEO & Director recently bought AU$128k worth of stock

Actinogen Medical Limited Announces Positive XanaMIA Results for Xanamem

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Expects Top-Line Results for the XanaMIA Part A Trial to Be Available in April 1

Actinogen Medical Announces Enrolment Reach in the XanaMIA Part A Trial of 105 Participants

We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn

Actinogen Medical Limited Completes Global Patent Family Grant

Actinogen Medical Limited Announces First Patient Enrolled in XanaMIA Trial

Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business

Actinogen Receives Positive Pre-IND FDA Advice for FXS

Actinogen Medical Receives Ethics Committee Approval for XanaMIA study

We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow

Actinogen Medical Limited Appoints Steven Gourlay as CEO

MD, CEO & Director John Ketelbey has left the company

MD, CEO & Director John Ketelbey has left the company

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Wins FDA Actinogen's Drug Xanamem Rare Paediatric Disease Designation for the Treatment of Fragile X Syndrome

How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?

Actinogen Medical Limited Announces Two New Clinical Trials

Actinogen Medical Limited Appoints Jeff Carter as Chief Financial Officer

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin